IRIS PubliCatt

Guidi, Luisa
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.328
EU - Europa 2.323
AS - Asia 724
AF - Africa 9
Continente sconosciuto - Info sul continente non disponibili 3
SA - Sud America 3
Totale 5.390
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.312
DE - Germania 938
SE - Svezia 443
CN - Cina 312
UA - Ucraina 236
SG - Singapore 212
IT - Italia 186
IE - Irlanda 126
FR - Francia 124
GB - Regno Unito 95
ID - Indonesia 73
IN - India 68
FI - Finlandia 52
PL - Polonia 32
RU - Federazione Russa 32
TR - Turchia 28
BE - Belgio 21
CA - Canada 14
IR - Iran 13
NL - Olanda 8
CI - Costa d'Avorio 7
JP - Giappone 7
HK - Hong Kong 6
CH - Svizzera 4
CZ - Repubblica Ceca 4
ES - Italia 4
PT - Portogallo 4
BG - Bulgaria 3
GR - Grecia 3
HU - Ungheria 3
A2 - ???statistics.table.value.countryCode.A2??? 2
BR - Brasile 2
BZ - Belize 2
PH - Filippine 2
TW - Taiwan 2
AL - Albania 1
DK - Danimarca 1
EU - Europa 1
NO - Norvegia 1
RO - Romania 1
RS - Serbia 1
SC - Seychelles 1
TN - Tunisia 1
VE - Venezuela 1
VN - Vietnam 1
Totale 5.390
Salva come PNG Salva come JPEG
Città #
Chandler 554
Ashburn 179
Singapore 170
Jacksonville 167
Dublin 123
San Mateo 122
Dearborn 107
Ann Arbor 101
New York 90
Jakarta 73
Nanjing 71
Wilmington 62
Cattolica 59
Nürnberg 59
Boston 49
Munich 42
Milan 41
Bremen 34
Houston 34
Princeton 34
Lawrence 33
Beijing 32
Izmir 27
Moscow 26
Los Angeles 25
Marseille 24
Lancaster 22
Fairfield 21
Kraków 21
Nanchang 20
Brussels 19
Seattle 19
Woodbridge 19
Redwood City 18
Shenyang 17
Hangzhou 15
Augusta 14
Boardman 14
Changsha 14
Leawood 13
Mountain View 12
Hebei 11
Jiaxing 11
Warsaw 11
Kunming 10
Tianjin 10
Detroit 9
Norwalk 9
Pune 9
Redmond 9
Zhengzhou 9
Ardabil 8
Costa Mesa 8
Guangzhou 8
Helsinki 8
Shanghai 8
Abidjan 7
Andover 7
Cagliari 7
Toronto 7
University Park 7
Fremont 6
Jinan 6
San Jose 6
Washington 6
Hefei 5
Indiana 5
London 5
Rome 5
Sacramento 5
Hong Kong 4
Kish 4
Millbury 4
Bengaluru 3
Brno 3
Cambridge 3
Edinburgh 3
Frankfurt am Main 3
Lanzhou 3
Ottawa 3
San Diego 3
Simi Valley 3
Sofia 3
Tokyo 3
A Coruña 2
Amsterdam 2
Belize City 2
Berlin 2
Bologna 2
Budapest 2
Central 2
Changchun 2
Chicago 2
Chiswick 2
Corsico 2
Gunzenhausen 2
Henderson 2
Lappeenranta 2
Las Vegas 2
Lille 2
Totale 2.895
Salva come PNG Salva come JPEG
Nome #
A) Prevalence of the K469E polymorphism of intercellular adhesion molecule 1 gene in Italian patients with inflammatory bowel disease. 319
FOXP3⁺ T regulatory cell modifications in inflammatory bowel disease patients treated with anti-TNFα agents 153
Comparison of Quantiferon-TB Gold versus tuberculin skin test for tuberculosis screening in inflammatory bowel disease patients. 144
Paradoxical psoriasis in a large cohort of patients with inflammatory bowel disease receiving treatment with anti-TNF alpha: 5-year follow-up study 144
Prevention of postoperative recurrence with azathioprine or infliximab in patients with Crohn's disease: an open-label pilot study 139
Early atherosclerosis in patients with inflammatory bowel disease. 135
Immune response to influenza A/H1N1 vaccine in inflammatory bowel disease patients treated with anti TNF-α agents: Effects of combined therapy with immunosuppressants. 135
Infliximab in Steroid-dependent Ulcerative Colitis: Effectiveness and Predictors of Clinical and Endoscopic Remission. 135
Long-term combination therapy with infliximab plus azathioprine predicts sustained steroid-free clinical benefit in steroid-dependent ulcerative colitis. 130
Development of psoriasis scalp with alopecia during treatment of Crohn's disease with infliximab and rapid response to both diseases to ustekinumab 123
-Increased carotid intima-media thickness in patients with inflammatory bowel disease 122
Achievement of sustained deep remission with adalimumab in a patient with both refractory ulcerative colitis and seronegative erosive rheumatoid arthritis 120
Prevalence and natural history of hepatitis B and C infections in a large population of IBD patients treated with anti-tumor necrosis factor-α agents 114
Sonography of the small bowel after oral administration of fluid: an assessment of the diagnostic value of the technique 112
Dermatological adverse reactions during anti-TNF treatments: Focus on inflammatory bowel disease. 106
Ileal Crohn's disease: CEUS determination of activity 105
Faecal calprotectin assay after induction with anti-Tumour Necrosis Factor α agents in inflammatory bowel disease: Prediction of clinical response and mucosal healing at one year. 101
Use of infliximab in particular clinical settings: management based on current evidence. 99
Ileal Crohn disease: mural microvascularity quantified with contrast-enhanced US correlates with disease activity 99
Magnesium Absorption in Intestinal Cells: Evidence of Cross-Talk between EGF and TRPM6 and Novel Implications for Cetuximab Therapy 98
Enteroclysis CT and PEG-CT in patients with previous small-bowel surgical resection for Crohn's disease: CT findings and correlation with endoscopy 96
Ileal Crohn disease: mural microvascularity quantified with contrast-enhanced US correlates with disease activity 94
A case of pyoderma gangrenosum with ulcerative colitis treated with combined approach: infliximab and surgery 91
Anti-TNF-alpha therapies do not increase early postoperative complications in patients with inflammatory bowel disease. An Italian single-center experience. 88
Therapeutic drug monitoring of anti-TNF-α agents in inflammatory bowel diseases 87
Benefit–risk assessment of golimumab in the treatment of refractory ulcerative colitis 84
A case of hereditary hemorrhagic telangiectasia associated with Crohn's disease successfully treated with infliximab. 83
What is the best way to manage screening for infections and vaccination of inflammatory bowel disease patients? 77
Management of perianal fistulas in Crohn's disease: an up-to-date review 76
Mucosal healing in ulcerative colitis: surveillance or colectomy? 71
Therapeutic drug monitoring is more cost-effective than a clinically-based approach in the management of loss of response to infliximab in inflammatory bowel disease: an observational multi-centre study. 71
AID in aging and autoimmune diseases 70
Anti-TNF alpha therapy in the management of extraintestinal manifestation of inflammatory bowel disease. 67
Early vedolizumab trough levels predict treatment persistence over the first year in inflammatory bowel disease 67
Ileal Crohn disease: mural microvascularity quantified with contrast-enhanced US correlates with disease activity 66
Adalimumab in active ulcerative colitis: a "real-life" observational study 65
Clinical management of rheumatologic conditions co-occurring with inflammatory bowel diseases 65
Comparison of performances of infliximab biosimilars CT-P13 versus SB2 in the treatment of inflammatory bowel diseases: a real-life multicenter, observational study in Italy 64
Early vedolizumab trough levels predict treatment persistence over the first year in inflammatory bowel disease 59
TRPM7 Is Overexpressed in Human IBD-Related and Sporadic Colorectal Cancer and Correlates with Tumor Grade 58
Neuropeptide Y plasma levels and immunological changes during academic stress 56
Paradoxical arthritis occurring during anti-TNF in patients with Inflammatory Bowel Disease: histological and immunological features of a complex synovitis. 56
Transition of inflammatory bowel disease patients from pediatric to adult care: an observational study on a joint-visits approach 56
Inflammatory Bowel Disease Phenotype as Risk Factor for Cancer in a Prospective Multicentre Nested Case-Control IG-IBD Study. 55
The Italian registry of therapeutic apheresis: Granulocyte-monocyte apheresis in the treatment of inflammatory bowel disease. A multicentric study 53
Impact of COVID-19 pandemic on the daily management of biotechnological therapy in inflammatory bowel disease patients: Reorganisational response in a high-volume Italian inflammatory bowel disease centre 53
[Soluble factors with immunosuppressive activity in human neoplasms] 51
Management of difficult-to-treat patients with ulcerative colitis: focus on adalimumab 51
Changes in admissions, and hospitalization outcomes of IBD patients in an Italian tertiary referral center over a 13-year period 51
Infliximab three-dose induction regimen in severe corticosteroid-refractory ulcerative colitis: Early and late outcome and predictors of colectomy 50
Acute cytomegalovirus infection as a possible trigger for pulmonary thromboembolism in a patient with steroid-refractory ulcerative colitis. 50
Therapeutic drug monitoring with vedolizumab in inflammatory bowel disease 50
Anti TNF-α therapy for ulcerative colitis: current status and prospects for the future 49
Predictors of clinical response in patients with ulcerative colitis treated with granulocyte-monocyte apheresis: analysis of the apheresis registry data 48
Dual Targeted Therapy: a possible option for the management of refractory Inflammatory Bowel Disease 48
Harmful effects and potential benefits of anti-tumor necrosis factor (TNF)-α on the liver 42
Watery stools and metabolic acidosis 42
Functional type 1 regulatory T cells develop regardless of FOXP3 mutations in patients with IPEX syndrome. 41
Novel trends with biologics in inflammatory bowel disease: sequential and combined approaches 41
Switching from IFX originator to biosimilar CT-P13 does not impact effectiveness,safety and immunogenicity in a large cohort of IBD patients 41
The PROSit cohort of infliximab biosimilar in IBD: A prolonged follow-up on the effectiveness and safety across Italy 39
Cancer Risk in Inflammatory Bowel Disease: A 6-Year Prospective Multicenter Nested Case-Control IG-IBD Study 39
Novel trends with biologics in inflammatory bowel disease: sequential and combined approaches 39
Predictors and early markers of response to biological therapies in inflammatory bowel diseases 39
Linking estrogen receptor β expression with inflammatory bowel disease activity 37
Switching from IFX originator to biosimilar CT-P13 does not impact effectiveness,safety and immunogenicity in a large cohort of IBD patients 37
Sustained clinical efficacy and mucosal healing of thiopurine maintenance treatment in ulcerative colitis: A real-life study 36
The PROSIT-BIO Cohort: A Prospective Observational Study of Patients with Inflammatory Bowel Disease Treated with Infliximab Biosimilar. 22
Fever of unknown origin due to Coxiella burnetii, an unexpected guest in primary sclerosing cholangitis 18
Combined therapy with infliximab and seton drainage for perianal fistulizing Crohn's disease with anal endosonographic monitoring: A single-centre experience 15
Serum levels of metalloproteinases and their inhibitors in nonalcoholic steatohepatitis 13
Small bowel diseases 5
Small bowel diseases 4
Totale 5.459
Salva come PNG Salva come JPEG
Categoria #
all - tutte 22.781
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 22.781
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020478 0 0 0 0 52 109 62 31 55 23 102 44
2020/2021480 21 49 15 56 59 11 44 17 60 17 117 14
2021/2022646 55 45 9 107 16 14 8 116 19 27 106 124
2022/20231.376 184 193 96 233 109 159 54 115 172 10 33 18
2023/2024639 30 185 18 46 17 112 25 38 10 22 62 74
2024/2025294 23 42 117 18 94 0 0 0 0 0 0 0
Totale 5.459